| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 29 | 2023 | 16215 | 1.860 |
Why?
|
| Medication Adherence | 5 | 2024 | 513 | 1.840 |
Why?
|
| Antineoplastic Agents, Hormonal | 7 | 2022 | 841 | 1.450 |
Why?
|
| Receptors, G-Protein-Coupled | 4 | 2022 | 485 | 1.410 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2019 | 637 | 1.310 |
Why?
|
| Oncogene Proteins | 2 | 2021 | 367 | 1.190 |
Why?
|
| Receptor, ErbB-2 | 9 | 2023 | 2651 | 1.120 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2015 | 770 | 0.940 |
Why?
|
| Social Class | 1 | 2024 | 324 | 0.820 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2022 | 6 | 0.810 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 43 | 0.790 |
Why?
|
| Receptors, Estrogen | 8 | 2020 | 2170 | 0.750 |
Why?
|
| Thalidomide | 1 | 2024 | 597 | 0.720 |
Why?
|
| Prescription Drugs | 2 | 2019 | 61 | 0.710 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2022 | 5408 | 0.690 |
Why?
|
| Receptors, Dopamine D1 | 3 | 2005 | 89 | 0.680 |
Why?
|
| Estrogen Receptor alpha | 2 | 2022 | 692 | 0.670 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 232 | 0.630 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 529 | 0.560 |
Why?
|
| Estrogen Antagonists | 2 | 2018 | 188 | 0.510 |
Why?
|
| Quinolines | 1 | 2019 | 402 | 0.500 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2005 | 121 | 0.500 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 74 | 0.490 |
Why?
|
| Mucositis | 1 | 2015 | 149 | 0.480 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 557 | 0.480 |
Why?
|
| Tamoxifen | 6 | 2022 | 875 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 10400 | 0.460 |
Why?
|
| Cancer Survivors | 2 | 2018 | 742 | 0.450 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 14617 | 0.450 |
Why?
|
| Acneiform Eruptions | 1 | 2013 | 7 | 0.440 |
Why?
|
| Thiazolidinediones | 2 | 2005 | 147 | 0.440 |
Why?
|
| Glutamine | 1 | 2015 | 324 | 0.440 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 861 | 0.440 |
Why?
|
| Aromatase Inhibitors | 4 | 2020 | 311 | 0.420 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 2328 | 0.410 |
Why?
|
| Cytotoxins | 1 | 2012 | 65 | 0.400 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2013 | 271 | 0.400 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2013 | 219 | 0.400 |
Why?
|
| Ketones | 1 | 2012 | 57 | 0.400 |
Why?
|
| Furans | 1 | 2012 | 102 | 0.390 |
Why?
|
| Female | 34 | 2024 | 148940 | 0.380 |
Why?
|
| RANK Ligand | 1 | 2012 | 115 | 0.380 |
Why?
|
| Drug Eruptions | 1 | 2013 | 271 | 0.370 |
Why?
|
| Quinazolines | 3 | 2015 | 956 | 0.350 |
Why?
|
| Heterografts | 4 | 2022 | 738 | 0.340 |
Why?
|
| Estradiol | 4 | 2022 | 827 | 0.310 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 65 | 0.310 |
Why?
|
| Epothilones | 1 | 2008 | 55 | 0.310 |
Why?
|
| Humans | 40 | 2024 | 270740 | 0.310 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 14849 | 0.300 |
Why?
|
| Palliative Care | 1 | 2019 | 2178 | 0.290 |
Why?
|
| Obesity | 3 | 2023 | 2904 | 0.290 |
Why?
|
| Microtubules | 1 | 2008 | 329 | 0.280 |
Why?
|
| Estrogens | 3 | 2022 | 805 | 0.280 |
Why?
|
| Cell Membrane | 3 | 2005 | 878 | 0.280 |
Why?
|
| Postmenopause | 3 | 2023 | 375 | 0.260 |
Why?
|
| Dopamine | 2 | 2004 | 332 | 0.260 |
Why?
|
| Cell Proliferation | 5 | 2022 | 7238 | 0.250 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2005 | 46 | 0.250 |
Why?
|
| Mice | 11 | 2022 | 35600 | 0.240 |
Why?
|
| Animals | 15 | 2022 | 61956 | 0.240 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2004 | 41 | 0.230 |
Why?
|
| Administration, Oral | 2 | 2020 | 1608 | 0.230 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2004 | 133 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 16689 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 210 | 0.200 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2021 | 38 | 0.190 |
Why?
|
| Transplantation, Autologous | 3 | 2013 | 2067 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 30998 | 0.190 |
Why?
|
| Aged | 10 | 2024 | 73333 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 1302 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 4000 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 7044 | 0.180 |
Why?
|
| Minority Groups | 1 | 2023 | 328 | 0.180 |
Why?
|
| Retrospective Studies | 6 | 2024 | 39890 | 0.180 |
Why?
|
| Medicare | 2 | 2023 | 926 | 0.180 |
Why?
|
| Middle Aged | 11 | 2024 | 90352 | 0.180 |
Why?
|
| G1 Phase | 1 | 2021 | 305 | 0.180 |
Why?
|
| Immunologic Factors | 1 | 2024 | 672 | 0.180 |
Why?
|
| Adult | 9 | 2024 | 82040 | 0.170 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 271 | 0.170 |
Why?
|
| Hyaluronan Receptors | 2 | 2018 | 248 | 0.170 |
Why?
|
| Signal Transduction | 7 | 2021 | 12103 | 0.160 |
Why?
|
| Polypharmacy | 1 | 2019 | 62 | 0.160 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 2665 | 0.160 |
Why?
|
| Cinnamates | 1 | 2018 | 29 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 4481 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 12033 | 0.160 |
Why?
|
| Thy-1 Antigens | 1 | 2018 | 52 | 0.160 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 191 | 0.160 |
Why?
|
| Metformin | 1 | 2022 | 393 | 0.150 |
Why?
|
| Keratins | 1 | 2019 | 340 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2009 | 2810 | 0.150 |
Why?
|
| Neoplasms | 2 | 2015 | 15927 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2019 | 33737 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 347 | 0.140 |
Why?
|
| Purines | 1 | 2018 | 271 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2022 | 9042 | 0.140 |
Why?
|
| Cell Separation | 1 | 2019 | 609 | 0.140 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 217 | 0.140 |
Why?
|
| Mice, SCID | 2 | 2019 | 1826 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2018 | 223 | 0.140 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 2196 | 0.140 |
Why?
|
| Transcriptome | 2 | 2016 | 1963 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 335 | 0.140 |
Why?
|
| Atrophic Vaginitis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 65 | 0.140 |
Why?
|
| Receptors, Progesterone | 2 | 2020 | 1604 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2021 | 4329 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 369 | 0.140 |
Why?
|
| Rats | 4 | 2008 | 6441 | 0.140 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1553 | 0.130 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 5315 | 0.130 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 41 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1076 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 249 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2021 | 1033 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7381 | 0.120 |
Why?
|
| Rats, Zucker | 2 | 2005 | 59 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 5231 | 0.120 |
Why?
|
| Neutropenia | 2 | 2009 | 1006 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2019 | 1275 | 0.120 |
Why?
|
| Colforsin | 2 | 2004 | 64 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 3917 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1032 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2353 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 531 | 0.120 |
Why?
|
| Male | 9 | 2024 | 128315 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2019 | 345 | 0.110 |
Why?
|
| Pandemics | 1 | 2023 | 1610 | 0.110 |
Why?
|
| Mastectomy | 1 | 2020 | 1553 | 0.110 |
Why?
|
| Breast | 1 | 2020 | 1369 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 78 | 0.110 |
Why?
|
| Pain Management | 1 | 2019 | 712 | 0.110 |
Why?
|
| Blood Component Removal | 1 | 2013 | 119 | 0.110 |
Why?
|
| Indoles | 1 | 2018 | 1028 | 0.110 |
Why?
|
| Texas | 1 | 2024 | 6449 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 850 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 3046 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 14012 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1412 | 0.100 |
Why?
|
| Risk Factors | 4 | 2020 | 17888 | 0.100 |
Why?
|
| Endocrine System | 1 | 2011 | 36 | 0.100 |
Why?
|
| Taxoids | 1 | 2015 | 1015 | 0.100 |
Why?
|
| Denosumab | 1 | 2012 | 72 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2018 | 1875 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2573 | 0.090 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2011 | 110 | 0.090 |
Why?
|
| Risk | 1 | 2015 | 1939 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 704 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2015 | 2311 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2399 | 0.090 |
Why?
|
| Leukopoiesis | 1 | 2009 | 7 | 0.090 |
Why?
|
| Filgrastim | 1 | 2009 | 194 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 2211 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2005 | 1269 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 6177 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2015 | 1542 | 0.080 |
Why?
|
| Ketoglutaric Acids | 1 | 2009 | 44 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 1942 | 0.080 |
Why?
|
| California | 1 | 2009 | 212 | 0.080 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2009 | 44 | 0.080 |
Why?
|
| Hospitals, University | 1 | 2009 | 218 | 0.080 |
Why?
|
| Depression | 1 | 2019 | 1730 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 622 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1468 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2005 | 732 | 0.080 |
Why?
|
| United States | 2 | 2023 | 15861 | 0.080 |
Why?
|
| Insulin | 2 | 2005 | 1483 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2010 | 572 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2015 | 2250 | 0.080 |
Why?
|
| Biological Assay | 1 | 2009 | 178 | 0.080 |
Why?
|
| Young Adult | 3 | 2019 | 22251 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3245 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2650 | 0.070 |
Why?
|
| Dogs | 1 | 2008 | 1160 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 561 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 979 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2011 | 2090 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 547 | 0.060 |
Why?
|
| CD24 Antigen | 2 | 2018 | 88 | 0.060 |
Why?
|
| G-Protein-Coupled Receptor Kinase 4 | 1 | 2005 | 2 | 0.060 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2005 | 57 | 0.060 |
Why?
|
| Recurrence | 1 | 2013 | 4878 | 0.060 |
Why?
|
| Radioligand Assay | 1 | 2004 | 57 | 0.060 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2004 | 43 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 401 | 0.060 |
Why?
|
| Second Messenger Systems | 1 | 2004 | 34 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 1034 | 0.060 |
Why?
|
| Microvilli | 1 | 2004 | 88 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2020 | 6764 | 0.060 |
Why?
|
| Cytokines | 1 | 2013 | 2825 | 0.060 |
Why?
|
| Macrolides | 1 | 2004 | 65 | 0.060 |
Why?
|
| Precipitin Tests | 1 | 2004 | 350 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 61 | 0.060 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2004 | 75 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 240 | 0.060 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2004 | 39 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 3028 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1456 | 0.060 |
Why?
|
| Prognosis | 3 | 2019 | 22505 | 0.060 |
Why?
|
| Benzazepines | 1 | 2004 | 116 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 589 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 135 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2004 | 378 | 0.050 |
Why?
|
| Time Factors | 3 | 2015 | 13006 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 3844 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 13414 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2004 | 341 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 5149 | 0.050 |
Why?
|
| Sodium | 1 | 2004 | 323 | 0.050 |
Why?
|
| Length of Stay | 1 | 2009 | 2007 | 0.050 |
Why?
|
| Protein Transport | 1 | 2004 | 737 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2012 | 2928 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3409 | 0.040 |
Why?
|
| Body Weight | 1 | 2005 | 1307 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2020 | 100 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 3216 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 2374 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 10708 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 2400 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 2156 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2005 | 1568 | 0.040 |
Why?
|
| Mutation | 1 | 2019 | 15912 | 0.040 |
Why?
|
| Premenopause | 1 | 2018 | 136 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2004 | 3584 | 0.040 |
Why?
|
| Survival Rate | 1 | 2011 | 12541 | 0.040 |
Why?
|
| Apoptosis | 1 | 2012 | 7757 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2005 | 4942 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 277 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2019 | 743 | 0.030 |
Why?
|
| Administration, Intravaginal | 1 | 2016 | 13 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4821 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 79 | 0.030 |
Why?
|
| Disease Progression | 2 | 2018 | 6867 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 15218 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 2454 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 2394 | 0.030 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2013 | 175 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 736 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2022 | 6224 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 1356 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 226 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2013 | 255 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 676 | 0.020 |
Why?
|
| Stem Cells | 1 | 2018 | 1216 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 1441 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 378 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5457 | 0.020 |
Why?
|
| Terfenadine | 1 | 2010 | 2 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 1021 | 0.020 |
Why?
|
| Quinidine | 1 | 2010 | 13 | 0.020 |
Why?
|
| Propanolamines | 1 | 2010 | 45 | 0.020 |
Why?
|
| Digoxin | 1 | 2010 | 53 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2012 | 896 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2375 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 379 | 0.020 |
Why?
|
| Titrimetry | 1 | 2009 | 11 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 2009 | 27 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2009 | 60 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2009 | 102 | 0.020 |
Why?
|
| Succinic Acid | 1 | 2009 | 27 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2009 | 48 | 0.020 |
Why?
|
| Adolescent | 1 | 2009 | 32767 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 3063 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 267 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 10265 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2018 | 2765 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 581 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1388 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1838 | 0.020 |
Why?
|
| Hydrazines | 1 | 2009 | 213 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 396 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3640 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 2220 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 9292 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 2101 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 4761 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 5051 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 1504 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 4372 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 4252 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2009 | 1718 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 6509 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 4644 | 0.010 |
Why?
|